07/28/2026
Seeing headlines that "FDA approved peptides?" Let's clear up what actually happened.
There has been a lot of excitement surrounding peptides like BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, but many of the headlines don't tell the full story.
Here's what patients should know:
An FDA advisory committee recently recommended that these six peptides be considered for inclusion on the 503A Bulks List, which is the list of substances traditional compounding pharmacies may eventually be permitted to use.
This is NOT FDA approval.
It also does not mean 503A pharmacies can begin compounding these peptides today.
The committee's vote is an important milestone, but several steps still need to occur before anything changes for patients.
What happens next?
✔️ The FDA reviews the advisory committee's recommendations.
✔️ The FDA determines whether to add each peptide to the 503A Bulks List.
✔️ Only after a final FDA decision could eligible 503A compounding pharmacies compound these peptides.
While there is optimism following the committee's recommendation, nothing changes today for patients seeking these products.
At Hobbs Pharmacy, we are committed to providing evidence-based, compliant care. We'll continue monitoring the FDA's decisions and will share updates as they become available so you can separate the headlines from the facts.
Have questions about peptides, compounded medications, or what these changes could mean for you? Our pharmacists are always happy to help.